Dr Panda is currently working as Senior Research Officer at the National Cancer Centre Singapore (NCCS). Dr. Panda trained in Dental Surgery at Institute of Dental Sciences, Siksha’O’Anusandhan Deemed to be University Bhubaneswar, India and did his Masters in Clinical Research from Tata Memorial Hospital (TMH), Mumbai in 2016. He was working as a Medical Research Fellow at TMH (2017-18) whereby he was involved in several prospective clinical trials in surgical, medical and radiation oncology, cancer epidemiological studies and clinical audits. He has worked extensively on conducting pharmaceutical and investigator-initiated clinical trials, clinical research methodologies, regulatory affairs (Indian, US-FDA, and European Medicines Agency), bioethics and patients’ rights and safety in clinical trials. Prior to joining NCCS, Dr Panda was instrumental in setting up the Clinical Research Secretariat at South Asia’s first proton therapy facility at Apollo Hospital group’s Apollo Proton Cancer Centre (APCC) in Chennai. He successfully designed and initiated 15 prospective clinical studies on proton therapy for various sites such as head and neck cancers, brain tumours, prostate cancers, thoracic cancers, paediatric cancers, bone and soft tissue cancers, breast cancers. He is a faculty and steering committee member for the Australia and Asia-Pacific Clinical Oncology Research Development (ACORD) initiative in Australia and has been awarded the Duke Scholar fellowship for Accelerating Anticancer Agent Development and Validation (2017) in Bethesda, Maryland, USA.. He has authored several national and international publications in high impact factor journals like the JAMA Oncology. He believes that providing affordable and world-class healthcare across the globe requires greater cooperation between oncology researchers and other stakeholders from low- and middle- income countries and high-income countries.